Replies to post #128959 on Biotech Values

[oc631]

I just read Feuerstein’s piece saying that VRUS might owe royalties to IDIX on its nuke IP, and I think there’s no substance to it. But this has nothing to do with the looming competition from ABT in all-oral HCV cocktails, which is presumably the reason for VRUS’ selloff today.

What do you find so appealing about ABT's all-oral offering?